Straits Times Index
3,367.90 +29.33 (+0.88%) S&P 500
5,475.79 +0.70 (+0.01%) Dow
39,114.26 -55.26 (-0.14%) Nasdaq
17,902.93 +23.63 (+0.13%) Bitcoin USD
61,816.18 -1,218.31 (-1.93%) CMC Crypto 200
1,309.96 -34.55 (-2.57%)
INDV Jul 2024 17.500 put
- PR Newswire
Indivior Announces the Publication of New Data on the Comparative Effectiveness of Intranasal (IN) Nalmefene (OPVEE 2.7mg) and IN Naloxone (4 mg) in a Translational Model Assessing the Impact of a Synthetic Opioid Overdose on Respiratory Depression and Cardiac Arrest
Indivior PLC (LSE/Nasdaq: INDV) today announced the publication of a modeling study in Frontiers in Psychiatry that predicts OPVEE (nalmefene) nasal spray (2.7 mg nalmefene, equivalent to 3 mg of nalmefene hydrochloride) resulted in larger reductions in the incidence of simulated cardiac arrest following overdose from high doses of potent synthetic opioids, compared to a 4 mg dose of IN naloxone.
- PR Newswire
Indivior Announces Dosing of First Subject with INDV-2000 in a Phase 2 Study Assessing the Safety and Efficacy of INDV-2000 in Individuals with Opioid Use Disorder
Indivior PLC (LSE/Nasdaq: INDV) today announced the dosing of the first subject with INDV-2000 in a Phase 2 double-blind, placebo controlled, randomized, dose-ranging study to assess the safety and efficacy of INDV-2000 over 3 months in treatment-seeking individuals with Opioid Use Disorder (OUD) (NCT06384157). The purpose of this proof-of-concept study is to measure safety and efficacy and to determine the dose-response relationship for INDV-2000 in participants with moderate to severe OUD who
- Simply Wall St.
With 59% ownership, Indivior PLC (LON:INDV) boasts of strong institutional backing
Key Insights Institutions' substantial holdings in Indivior implies that they have significant influence over the...
